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Abstract. Determination of the presence of epidermal growth 
factor receptor (EGFR) gene mutation is useful for predicting 
the efficacy of gefitinib. However, the survival rate following 
the initiation of treatment with gefitinib varies among indi-
viduals. A retrospective study was conducted to investigate the 
associations of the pretreatment serum pro-gastrin-releasing 
peptide (pro‑GRP) and plasma neuron‑specific enolase (NSE) 
levels to the patient survival rate following initiation of treat-
ment with gefitinib in non‑small cell lung cancer (NSCLC) 
patients receiving gefitinib treatment. Patients with NSCLC 
harboring EGFR gene mutations who received gefitinib therapy 
between 2004 and 2012 were included in the study. Data from 
a total of 41 patients were analyzed. The serum pro‑GRP 
level was measured in 31 patients and the plasma NSE in 
22 patients. The progression‑free survival (PFS) (P=0.013) and 
overall survival (OS) (P=0.014, log‑rank test) rates decreased 
as the plasma NSE level increased. Statistical analysis using a 
Cox proportional hazards regression model adjusted for age, 
gender, performance status (PS) and disease stage showed that 
higher NSE levels were associated with shorter PFS (P=0.021) 
and OS (P=0.0024). By contrast, no association was detected 
between the serum level of pro‑GRP and survival rate. The 
results suggest that pretreatment NSE measurement could be 
clinically useful in patients with NSCLC scheduled to receive 
gefitinib treatment.
Introduction
Epidermal growth factor receptor (EGFR) gene mutation is an 
important predictor of the response to EGFR‑tyrosine kinase 
inhibitor (EGFR‑TKI) treatment. Gefitinib treatment yields a 
longer progression‑free survival (PFS) rate than cytotoxic drug 
therapy in patients with non‑small cell lung cancer (NSCLC) 
harboring EGFR gene mutations, including exon 19 deletion 
and exon 21 L858R (1‑3). However, an important clinical 
problem is that in the majority of cases, the tumor cells soon 
acquire resistance to gefitinib.
Several mechanisms of acquired resistance to gefitinib 
have been proposed. Hepatocyte growth factor has been 
shown to induce resistance to gefitinib of lung adenocarci-
nomas harboring EGFR gene mutations (4). An investigation 
of 37 cases with acquired resistance to gefitinib revealed the 
presence of the EGFR T790 mutation, MET amplification, 
transition from NSCLC to small cell lung cancer (SCLC), or 
PIK3CA mutation in these cases (5).
Blood levels of pro‑gastrin releasing peptide (pro‑GRP) 
and neuron‑specific enolase (NSE) have been reported to 
be frequently elevated in patients with SCLC (6), and their 
measurement has been utilized for diagnosis or evaluation 
of the treatment outcomes in these patients. Furthermore, 
elevation of the pretreatment plasma NSE level has also been 
associated with poor outcomes in patients with NSCLC (7‑11).
We hypothesized that the blood level of pro‑GRP and/or 
NSE may be associated with the clinical course following 
initiation of gefitinib therapy in patients with NSCLC 
harboring EGFR gene mutations. To endorse its validity, the 
present retrospective study was conducted.
Patients and methods
Patient selection. The medical records of patients with NSCLC 
diagnosed between 2004 and 2012 were reviewed. The inclu-
sion criteria were as follows: i) Patients with cytologically 
or histologically confirmed NSCLC harboring activating 
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EGFR gene mutations and ii) patients treated with gefitinib. 
Patients who had received another EGFR‑TKI prior to the 
initiation of treatment with gefitinib were excluded. The study 
was approved by the Ethics Committee of the University of 
Toyama (Toyama, Japan).
Analysis for EGFR gene mutations, immunohistochemistry 
and clinical information. The presence/absence of EGFR gene 
mutations was analyzed by the PCR‑invader assay (BML, 
Inc., Tokyo, Japan). Plasma NSE and serum pro‑GRP were 
measured by a commercial laboratory (SRL Inc., Tokyo, Japan). 
Plasma NSE was measured by a radioimmunoassay method 
before December 2013 and by an electrochemiluminescence 
method from December 2013. Therefore, the values measured 
by radioimmunoassay were revised using the following 
equation: y = 1.060x + 0.665 (y, value measured by the 
electrochemiluminescence method; x, value measured by the 
radioimmunoassay method), developed by SRL, Inc. (http://www.
srl.info/srlinfo/srlnews/2011/pdf/2011‑24.pdf). The serum 
pro‑GRP level was measured by a chemiluminescent enzyme 
immunoassay method.
From the medical records, the clinical information 
regarding the patients was reviewed, including the age, gender, 
performance status (PS) and disease stage. Stage was classi-
fied as postoperative recurrence and as stage I‑IV according 
to the tumor‑node‑metastasis classification. Determination 
of disease progression was based on computed tomography, 
according to the Response Evaluation Criteria in Solid 
Tumors, version 1.1.
Immunohistochemical (IHC) staining of the tumor speci-
mens was performed for NSE and cluster of differentiation 56 
(CD56). NSE staining was performed using the anti‑rabbit 
NSE polyclonal antibody (rabbit polyclonal, prediluted; 
Nichirei Biosciences, Inc., Tokyo, Japan) and CD56 staining 
used the anti‑mouse monoclonal antibody (Clone 1B6, 
prediluted; Nichirei Biosciences, Inc.). Immunoperoxidase 
reactions were performed using the Ventana BenchMark GX 
automated immunostainer (Ventana Medical System, Tucson, 
AZ, USA), in accordance with the manufacturer's instructions. 
The pathological diagnoses and results of assessment of the 
tumor immunoreactivity were reviewed by two investigators 
and reported by consensus.
Statistical analysis. Survival curves were drawn using 
the Kaplan‑Meier method to analyze the PFS and overall 
survival (OS) rate of the patients. The PFS was calculated 
as the time from the initiation of treatment with gefitinib to 
the date of mortality or detection of PD and censored at the 
date of the last visit of the patients not confirmed to have PD. 
The OS was calculated from the initiation of treatment with 
gefitinib to the date of mortality and censored at the date of 
the last visit of the patients who had not succumbed. The PFS 
and OS were compared by the log‑rank test. Patients were 
divided based on the median tumor marker levels. Independent 
associations were analyzed using a Cox proportional hazards 
regression model adjusted for age, gender, PS, EGFR status 
and the disease stage. Statistical analysis was performed using 
the statistical package JMP 10.0.2 (SAS Institute, Cary, NC, 
USA). P<0.05 was considered to indicate a statistically signifi-
cant difference.
Results
Patient characteristics. A total of 554 patients were diag-
nosed as having NSCLC between 2004 and 2012 at the First 
Department of Internal Medicine, University of Toyama. Of 
these, 74 patients were treated with gefitinib, of whom 41 with 
activating EGFR gene mutations were included in this study.
Table I shows the patient characteristics. Seventeen 
patients (41.5%) were male and 19 (46.3%) had a history of 
smoking. The histological diagnosis was adenocarcinoma 
in 38 patients (92.7%). In regard to the EGFR gene muta-
tion, exon 19 deletion was detected in 23 (56.1%) tumors, 
exon 21 L858R point mutation in 15 (36.6%) cases and 
exon 18 point mutation in 3 (7.3%) patients. Of the patients, 
32 (78.0%) were classified as having stage IIIB or IV disease 
and 9 (22.0%) were classified as having postoperative recur-
rence. Gefitinib was administered as the first‑line therapy in 
Table I. Patient characteristics.
Characteristics Values
Patients, n 41
Age, median years (interquartile range) 68 (64‑79.5)
  ≥70, n (%) 18 (43.9)
Gender, n (%)
  Male 17 (41.5)
  Female 24 (58.5)
Histology, n (%)
  Adenocarcinoma 38 (92.7)
  Non‑adenocarcinoma 3 (7.3)
EGFR status, n (%)
  Major mutation
    Exon 19 del 23 (56.1)
    Exon 21 L858R 15 (36.6)
  Minor mutation
    Exon 18 point mutation 3 (7.3)
PS, n (%)
  0‑1 28 (68.3)
  ≥2 13 (31.7)
Smoking status, n (%)
  Yes 19 (46.3)
  No 22 (53.7)
Stage, n (%)
  IIIB/IV 32 (78.0)
  Postoperative recurrence   9 (22.0)
Prior regimen, n (%)
  0 34 (83.0)
  1   7 (17.0)
EGFR, epidermal growth factor receptor; PS, performance status.
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34 (82.9%) patients and as second‑line therapy in seven (17.1%). 
The median (interquartile range) serum value of pro‑GRP in 
31 patients was 31.4 (25.8‑44.8) pg/ml and the median (inter-
quartile range) plasma value of NSE in the 22 patients was 
12.1 (9.8‑16.0) ng/ml. The patients were divided into three 
groups according to the median levels of the tumor markers, as 
follows: i) High level group, comprising those with high serum 
levels of the tumor markers, ii) low level group, comprising 
those with low serum levels of the tumor markers and iii) an 
‘unknown' group, comprising patients whose tumor marker 
levels were unknown.
Survival rates. The PFS and OS in the 41 patients were 
9.6 and 22.6 months, respectively (Fig. 1). Patients with higher 
NSE levels (high level group) showed shorter PFS (P=0.013) 
and OS (P=0.014) values according to the log‑rank test, than 
those of the patients with lower NSE levels (low level group) and 
the group in which the NSE levels were unknown (‘unknown' 
group), whereas no association was observed between the 
serum pro‑GRP level and the PFS or OS (Fig. 2). Table II shows 
the results of analysis using the Cox proportional hazards 
regression model. This analysis identified pretreatment NSE 
as being significantly associated with the PFS (P=0.021) and 
OS (P=0.0024), independent of the age, gender, EGFR status, 
PS or disease stage.
IHC staining. IHC staining was performed in 27 cases. All 
27 showed positive staining for NSE and negative staining for 
CD56. Thus, there were no significant associations between 
the plasma NSE levels and the findings of IHC.
Discussion
In the present study, the univariate and multivariate analyses 
revealed the existence of an association between the pretreat-
ment plasma NSE level and patient survival rate. However, no 
association was observed between the serum pro‑GRP level 
and survival rate. To investigate the neuroendocrine properties 
of the tumor cells, IHC analysis was conducted.
NSE is an isozyme of the intracytoplasmic enzyme 
enolase, which was first identified in an extract of mouse brain 
tissue (12) and later shown to be elevated in neuroendocrine 
tumors, including SCLC. By contrast, in patients with NSCLC, 
the plasma NSE level has been shown to be associated with the 
Figure 1. Kaplan‑Meier curve for all 41 patients with NSCLC receiving gefitinib therapy. The (A) PFS and (B) OS in the 41 patients were 9.6 and 22.6 months, 
respectively. NSCLC, non‑small cell lung cancer; PFS, progression‑free survival; OS, overall survival.
Figure 2. Kaplan‑Meier curve for each patient group divided according to the tumor marker level. Patients with (A) higher NSE levels had a shorter PFS 
than those with (B) lower PFS levels. No association was observed in the pro‑GRP levels in (A) PFS and (B) OS. PFS, progression‑free survival; OS, overall 
survival; NSE, neuron‑specific enolase; pro‑GRP, pro‑gastrin‑releasing peptide.
  A   B
  C   D
  A   B
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patient survival rate. This association was observed in patients 
with NSCLC, regardless of whether they were treated by 
surgical resection, radiation therapy or chemotherapy (7‑11). 
Furthermore, recently it has been reported that a higher 
pretreatment NSE level was associated with a shorter survival 
duration following the initiation of gefitinib in non‑selective 
patients with NSCLC (13). In the present study the association 
between the plasma NSE level and the prognosis was examined 
in a specific patient population and confirmed the existence of 
the same association in patients with NSCLC harboring EGFR 
mutations and receiving gefitinib treatment. This association 
is noteworthy, in view of transition to SCLC being reported 
as one of the mechanisms of acquisition of resistance to gefi-
tinib (5).
According to previous studies, plasma NSE elevation in 
NSCLC patients may reflect the heterogeneity of NSCLC 
and a neuroendocrine nature of the tumor. However, consis-
tent with previous studies (14,15), no association was found 
between the plasma NSE level and the presence of neuroen-
docrine markers, including NSE and CD56, as determined by 
IHC. Although the reason for this inconsistency is unclear, it 
could be attributable to the difficulty in quantitative measure-
ments by IHC. Indeed, although neuroendocrine markers 
have been detected in a considerable proportion of NSCLCs 
by IHC (16‑25), positive (18‑22) and negative findings (23‑25) 
have been reported in terms of the association between the 
IHC characteristics and the prognosis. Another explanation is 
that NSE expression is not identical to NSE secretion into the 
blood circulation, as NSE expression has also been detected 
by immunohistochemistry in various normal human tissues 
other than nervous and neuroendocrine tissues, including 
type II alveolar epithelial cells (26). It is possible that in all 
the patients in the present study, the tumor expressed NSE, as 
the tumor was an adenocarcinoma in the majority of patients. 
However, the mechanism of NSE secretion remains unclear.
Pro‑GRP is superior in sensitivity for the diagnosis of 
SCLC, but its association with the prognosis is weak (27,28). 
The present finding of a lack of any association between the 
serum pro‑GRP level and survival rate is in line with previous 
studies.
There were several limitations of the present study. 
Pretreatment plasma NSE was not measured in certain patients 
and the study sample was very small in size. Although we 
conducted multivariate analyses to adjust for confounding 
factors, it may be difficult to exclude the influences of factors 
other than the plasma NSE level on the patient survival rate. 
These findings should be interpreted with caution and further 
study in a larger study population is necessary. Second, we 
cannot speculate on the mechanism of elevation of the plasma 
NSE, as the IHC analysis revealed no significant findings. 
Third, although the pretreatment plasma NSE level is likely 
to be a prognostic factor in patients with NSCLC based on 
Table II. Analysis using a Cox proportional hazards regression model for assessing the association between plasma NSE and 
survival rate.
 PFS OS
 ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
Characteristics HR 95% CI P‑value HR 95% CI P‑value
Age, years
  ≥70 0.41 0.15‑1.10 0.079 1.25 0.39‑3.87 0.700
  <70 Reference   Reference
Gender
  Male 1.84 0.71‑4.83 0.209 1.37 0.44‑4.29 0.583
  Female Reference   Reference
EGFR status
  Major 0.89 0.18‑5.23 0.891 0.70 0.09‑6.71 0.740
  Minor Reference   Reference
PS
  ≥2 3.23 1.17‑9.07 0.024 8.74 2.35‑35.7 0.0013
  0-1 Reference   Reference
Stage
  Recurrence 0.47 0.10‑1.81 0.285 0.30 0.02‑1.94 0.230
  IIIB/IV Reference   Reference
NSE
  ≥13 4.69 1.27‑19.12 0.021 10.31 2.26‑59.2 0.0024
  Unknown 2.72 0.87‑10.14 0.088 3.08 0.80‑15.33 0.103
  <13 Reference   Reference
NSE, neuron specific enolase ; PFS, progression‑free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; EGFR, epidermal 
growth factor receptor; Major, major mutation including exon 19 del and exon 21 L858R; Minor, minor mutation; PS, performance status.
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previous studies, we cannot conclude from our observations 
whether it may be a predictive factor in patients with NSCLC 
receiving gefitinib treatment.
In conclusion, the results of the present study indicate the 
existence of an association between the pretreatment NSE 
level and survival rate in NSCLC patients receiving treatment 
with gefitinib. In the practical treatment of NSCLC, gefitinib 
therapy is one of the important treatment options for patients 
with NSCLC harboring EGFR gene mutations, regardless of the 
plasma NSE level. However, these findings suggest that measure-
ment of the pretreatment plasma NSE level can contribute to 
follow‑up planning in patients receiving gefitinib treatment.
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